论文部分内容阅读
目的 :检测原发性肝细胞癌患者血清中血管细胞黏附分子-1(vascular cell adhesion molecule-1,VCAM-1)的表达水平,并探讨其临床意义。方法:采用酶联免疫吸附测定法(enzyme-linked immunosorbent assay,ELISA)检测414例原发性肝细胞癌患者、120例肝炎患者和92例健康人血清中VCAM-1的表达水平,分析血清中VCAM-1的水平与肝细胞癌患者临床病理特征的相关性及与患者生存期的关系。结果 :肝细胞癌患者血清中VCAM-1的表达水平明显高于肝炎患者及健康对照组(P<0.000 1),且与血清中甲胎蛋白(alpha-fetoprotein,AFP)的表达水平密切相关(P=0.021)。Kaplan–Meier分析结果表明,VCAM-1表达水平高的肝细胞癌患者生存期短(P=0.023)。结论 :血清中VCAM-1的表达水平可以作为原发性肝细胞癌诊断和预后的潜在标志物。
Objective: To detect the expression of vascular cell adhesion molecule-1 (VCAM-1) in sera of patients with primary hepatocellular carcinoma and to investigate its clinical significance. Methods: The serum levels of VCAM-1 in 414 patients with primary hepatocellular carcinoma, 120 patients with hepatitis and 92 healthy controls were detected by enzyme-linked immunosorbent assay (ELISA) Correlation between the level of VCAM-1 and the clinicopathological features of hepatocellular carcinoma and its relationship with the survival of patients. Results: The expression of VCAM-1 in serum of hepatocellular carcinoma patients was significantly higher than that of hepatitis patients and healthy controls (P <0.000 1), and was closely related to the expression of alpha-fetoprotein (AFP) P = 0.021). Kaplan-Meier analysis showed that the survival of patients with high expression of VCAM-1 in hepatocellular carcinoma was shorter (P = 0.023). Conclusion: The expression of VCAM-1 in serum can be used as a potential marker for the diagnosis and prognosis of primary hepatocellular carcinoma.